Fig. 25From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (Abstract P6). Rimiducid-dependent MyD88/CD40 costimulation enhances antitumor activity of a first-generation CD123-specific CARBack to article page